Study population
研究人群
100 control samples (50 for the preliminary analysis and 50 for the masked analysis) were provided from the National Ovarian Cancer Early Detection Program (NOCEDP) clinic at Northwestern University Hospital (Chicago, IL, USA). 17 other control samples from anonymous women unaffected by cancer were provided by the Simone Protective Cancer Institute (Lawrenceville, NJ, USA). 100个对照样本（50个用于初步分析，50个用于隐蔽的分析）由西北大学医院（美国伊利诺斯州芝加哥）的卵巢癌早期检测计划（NOCEDP）的人口研究
西北大学医院（芝加哥，伊利诺州,美国）的全国卵巢癌早期检测程序(NOCEDP)诊所提供了100个控制样品(其中50个是初步分析，50个是隐蔽分析)。西蒙防护癌症研究所（劳伦斯维尔，纽约州，美国）提供了另外17个来自匿名女性的没有患癌的控制样本。其中，这17名女子患有各种病：子宫内膜异位症(7个),子宫肌瘤(3个)、窦炎(4个)、类风湿关节炎(2个)和溃疡性结肠炎(1个)。而这17个控制样本是在进行隐蔽分析的测试组。从NOCEDP得到的病例是经过以下最少的一个标准进行自我诊断的：①至少有一个患病的一级亲属；②家族性乳腺癌或卵巢癌综合征；③对BRCA1或BRCA2基因突变呈显性反应；④个人乳腺癌史。在匿名化的条件下，BRCA1/2的是不适用于这个分析的。选取高危人群是因为对于患卵巢癌风险不断增加的女性来讲，一个多样的管理选项的适用性尤为重要。
所有的妇女接受了年度的三维彩色多普勒超声的检查和CA125浓度的测量。如果她们已经有至少5年度的随访检查没有诊断为卵巢癌，那么有6个病例定义为未受影响。如果她们在妇科肿瘤学家进行病理阶段研究之前有病理分期血清样品，那么这些卵巢癌患者病例是合格的。
38%的没有患病的女性被超声波检测到简单的卵巢囊肿在(表1)。所有主要的卵巢癌上皮细胞亚型是典型代表，而从患有1期的女性所得来的6个癌症样本反映了分布1期癌细胞的分布情况。据报告显示，实验组都使用了口服避孕药，而检验结果在组间没有不同。在健康的没有症状的控制人口中，初步测试组的平均年龄是49岁(从21到75岁)，而隐蔽测试组的是48岁(从25到73岁)。这些年龄在本质上与那些测试组【(平均58岁(从29到82岁)和隐蔽测试组(平均59岁，从30到80岁)，包括那些1期癌症(平均57岁，从35到75岁)】。在这个年龄分布的基础上，两个测试组很好地代表了绝经前和绝经后的女性，因此绝经情况在检测中不应该是一个影响因素。
绝对人工翻译，不过部分专业名词可能翻得不是很好，本人不是理工科出身的。LZ可以自己对照修改一下啊~ 诊所提供。另外17个来自于没有受癌症影响的、姓名不详的妇女的样本则由西蒙娜保护癌症研究所（美国新泽西州劳伦斯维尔）提供。These 17 women had endometriosis (seven), uterine fibroids (three), sinusitis (four), rheumatoid arthritis (two), and ulcerative colitis (one) and were included in the masked validation set. 这17名妇女患有子宫内膜异位症（7人），子宫纤维瘤（3人），窦炎（4人），类风湿性关节炎（2人）和溃疡性肠炎（1人），并被包括在隐蔽的证实组中。Cases from the NOCEDP were self-referred under at least one of the following eligibility criteria: at least one affected first-degree relative; familial breast or ovarian cancer syndrome; positivity for BRCA1 or BRCA2 mutations; or personal history of breast cancer. 来自NOCEDP的案例在至少下面的资格标准之一下是自荐的：至少有一个受到影响的直系亲属； 家族性乳腺癌或卵巢癌综合征；BRCA1或BRCA2基因突变阳性；或者个人的乳腺癌史。BRCA1/2 status was not made available to this analysis under the conditions of anonymisation. The high-risk population was chosen because availability of a viable management option is particularly important for women who are at increased risk of development of ovarian cancer.
在anonymisation条件下BRCA1/2状态不能用于此分析。选择高风险人群是因为对于正处于卵巢癌发展高风险中的妇女来说，获得一个有生命力的管理选项特别重要。
All women received a yearly three-dimensional colour doppler flow ultrasound examination and measurement of CA125 concentration.6 Cases were defined as unaffected if they had had a minimum of 5 yearly follow-up examinations without diagnosis of ovarian cancer. Cases with ovarian cancer were eligible if they had had a serum sample banked before pathological staging by a gynaecological oncologist.
所有妇女都接受每年一次的、CA125浓度的三维彩色多普勒超声波检查和测量。6个案例被定义为未受影响的，因为她们至少有5年的随访检查是没有诊断出卵巢癌。带有卵巢癌的案例是符合资格的，条件是她们在被妇科肿瘤医生病例分期之前存有一份血清样本。
Simple ovarian cysts were detected by ultrasonography in 38% of the unaffected women (table 1). All major epithelial subtypes of ovarian cancer were represented, and six of the cancer samples were from women with stage I disease, which mirrors the distribution of stage I ovarian cancer in the community. Reported oral contraceptive use and parity was not different between the groups. 在38%的未受影响的妇女中，用超声波图像检测到了简单的卵巢囊肿（表1）。卵巢癌的所有主要的上皮细胞亚型都做了表示，而6个癌的样本来自于患有第一期疾病的妇女，这反映了第一期卵巢癌在公众中的分布。报道的口服避孕药的使用和不均衡在对照组之间没什么差别。The median age in the healthy symptom-free control population was 49 years (range 21–75) in the preliminary set and 48 years (25–73) in the masked validation set. These ages were not substantially different from those for the cancer patients in the preliminary set (median 58 years [range 29–82]) and in the masked validation set (59 [30–80]), including only those with stage I cancers (57 [35–75]). On the basis of the age distribution, premenopausal and postmenopausal women were ally represented in both groups, thus menopausal status should not have been a discriminator in the detection algorithm.在初步组中健康的无症状对照人群的中值年龄为49岁(范围21-75) ，而在隐蔽的证实组中为48岁（范围25－73）。这些年纪与初步组中癌症病人的年纪（中值58岁[范围29－82]）和隐蔽的证实组中癌症病人，包括仅为第一期癌症病人的年纪（59[30-80]没有重大差别。在年龄分布的基础上，绝经前和绝经后的妇女都在两个小组中有所代表，所以月经状态应该对检测算法不是鉴别的因素。
Study population
100 control samples (50 for the preliminary analysis and 50 for the masked analysis) were provided from the National Ovarian Cancer Early Detection Program (NOCEDP) clinic at Northwestern University Hospital (Chicago, IL, USA). 17 other control samples from anonymous women unaffected by cancer were provided by the Simone Protective Cancer Institute (Lawrenceville, NJ, USA). These 17 women had endometriosis (seven), uterine fibroids (three), sinusitis (four), rheumatoid arthritis (two), and ulcerative colitis (one) and were included in the masked validation set. Cases from the NOCEDP were self-referred under at least one of the following eligibility criteria: at least one affected first-degree relative; familial breast or ovarian cancer syndrome; positivity for BRCA1 or BRCA2 mutations; or personal history of breast cancer. BRCA1/2 status was not made available to this analysis under the conditions of anonymisation. The high-risk population was chosen because availability of a viable management option is particularly important for women who are at increased risk of development of ovarian cancer.
All women received a yearly three-dimensional colour doppler flow ultrasound examination and measurement of CA125 concentration.6 Cases were defined as unaffected if they had had a minimum of 5 yearly follow-up examinations without diagnosis of ovarian cancer. Cases with ovarian cancer were eligible if they had had a serum sample banked before pathological staging by a gynaecological oncologist.
Simple ovarian cysts were detected by ultrasonography in 38% of the unaffected women (table 1). All major epithelial subtypes of ovarian cancer were represented, and six of the cancer samples were from women with stage I disease, which mirrors the distribution of stage I ovarian cancer in the community. Reported oral contraceptive use and parity was not different between the groups. The median age in the healthy symptom-free control population was 49 years (range 21–75) in the preliminary set and 48 years (25–73) in the masked validation set. These ages were not substantially different from those for the cancer patients in the preliminary set (median 58 years [range 29–82]) and in the masked validation set (59 [30–80]), including only those with stage I cancers (57 [35–75]). On the basis of the age distribution, premenopausal and postmenopausal women were ally represented in both groups, thus menopausal status should not have been a discriminator in the detection algorithm.
人口研究
100控制样本（初步的分析和蒙面分析50 50）是由国家提供卵巢癌早期检测项目（NOCEDP）美国西北大学医院（芝加哥，IL，美国）的诊所。从17日因癌症不受影响匿名妇女的其他控制样本的保护提供了西蒙娜癌症研究所（劳伦斯维尔，新泽西州，美国）。这17名妇女子宫内膜异位症（7），子宫肌瘤（3），鼻窦炎（4），类风湿关节炎（2）和（1）和溃疡性结肠炎被列入蒙面验证设置。从自我的NOCEDP案件被下在至少一种下列资格条件：至少有一个首当其冲，一级亲属，家族乳腺癌或卵巢癌综合征称为;阳性的BRCA1基因或BRCA2基因突变;或是乳癌personal history。 BRCA1基因/ 2的地位并没有提供这一分析的条件下anonymisation。高危人群是一个可行的选择，因为管理选项的可用性，特别是妇女谁在卵巢癌的风险增加是重要的发展。
所有的妇女每年接受三维彩色多普勒超声检查和血清CA125 measurement concentration.6例作为不受影响未定义，如果他们有一个5年的后续行动无卵巢癌诊断考试最低。卵巢癌患者，如果他们有资格血清样品进行了前病理分期被储存在一个妇科肿瘤学家。
简单卵巢囊肿在超声检测的38（表1）％的妇女没有受到影响。所有卵巢上皮癌亚型为主要代表，以及6名癌症样品阶段的妇女，我病，它反映了卵巢癌的阶段，我在社会上的分布。报告的口服避孕药使用和不均衡是两组之间的差异。在健康的症状无控制人口的平均年龄为49岁（范围21-75）初步定在48岁（25-73集的蒙面验证）。这些年龄都没有本质在初步确定的癌症患者（平均58岁[范围的不同29-82]），在蒙面验证组（59 [30-80]），包括与舞台只有我癌症（ 57 [35-75]）。论年龄分布的基础上，绝经前和绝经后妇女的盟友两组代表，因此更年期的地位不应被检测算法中的一个鉴别。
Study population
100 control samples (50 for the preliminary analysis and 50 for the masked analysis) were provided from the National Ovarian Cancer Early Detection Program (NOCEDP) clinic at Northwestern University Hospital (Chicago, IL, USA). 17 other control samples from anonymous women unaffected by cancer were provided by the Simone Protective Cancer Institute (Lawrenceville, NJ, USA). These 17 women had endometriosis (seven), uterine fibroids (three), sinusitis (four), rheumatoid arthritis (two), and ulcerative colitis (one) and were included in the masked validation set. Cases from the NOCEDP were self-referred under at least one of the following eligibility criteria: at least one affected first-degree relative; familial breast or ovarian cancer syndrome; positivity for BRCA1 or BRCA2 mutations; or personal history of breast cancer. BRCA1/2 status was not made available to this analysis under the conditions of anonymisation. The high-risk population was chosen because availability of a viable management option is particularly important for women who are at increased risk of development of ovarian cancer.
All women received a yearly three-dimensional colour doppler flow ultrasound examination and measurement of CA125 concentration.6 Cases were defined as unaffected if they had had a minimum of 5 yearly follow-up examinations without diagnosis of ovarian cancer. Cases with ovarian cancer were eligible if they had had a serum sample banked before pathological staging by a gynaecological oncologist.
Simple ovarian cysts were detected by ultrasonography in 38% of the unaffected women (table 1). All major epithelial subtypes of ovarian cancer were represented, and six of the cancer samples were from women with stage I disease, which mirrors the distribution of stage I ovarian cancer in the community. Reported oral contraceptive use and parity was not different between the groups. The median age in the healthy symptom-free control population was 49 years (range 21–75) in the preliminary set and 48 years (25–73) in the masked validation set. These ages were not substantially different from those for the cancer patients in the preliminary set (median 58 years [range 29–82]) and in the masked validation set (59 [30–80]), including only those with stage I cancers (57 [35–75]). On the basis of the age distribution, premenopausal and postmenopausal women were ally represented in both groups, thus menopausal status should not have been a discriminator in the detection algorithm.
翻译：
人口研究
西北大学医院（芝加哥，伊利诺州,美国）的全国卵巢癌早期检测程序(NOCEDP)诊所提供了100个控制样品(其中50个是初步分析，50个是隐蔽分析)。西蒙防护癌症研究所（劳伦斯维尔，纽约州，美国）提供了另外17个来自匿名女性的没有患癌的控制样本。其中，这17名女子患有各种病：子宫内膜异位症(7个),子宫肌瘤(3个)、窦炎(4个)、类风湿关节炎(2个)和溃疡性结肠炎(1个)。而这17个控制样本是在进行隐蔽分析的测试组。从NOCEDP得到的病例是经过以下最少的一个标准进行自我诊断的：①至少有一个患病的一级亲属；②家族性乳腺癌或卵巢癌综合征；③对BRCA1或BRCA2基因突变呈显性反应；④个人乳腺癌史。在匿名化的条件下，BRCA1/2的是不适用于这个分析的。选取高危人群是因为对于患卵巢癌风险不断增加的女性来讲，一个多样的管理选项的适用性尤为重要。
所有的妇女接受了年度的三维彩色多普勒超声的检查和CA125浓度的测量。如果她们已经有至少5年度的随访检查没有诊断为卵巢癌，那么有6个病例定义为未受影响。如果她们在妇科肿瘤学家进行病理阶段研究之前有病理分期血清样品，那么这些卵巢癌患者病例是合格的。
38%的没有患病的女性被超声波检测到简单的卵巢囊肿在(表1)。所有主要的卵巢癌上皮细胞亚型是典型代表，而从患有1期的女性所得来的6个癌症样本反映了分布1期癌细胞的分布情况。据报告显示，实验组都使用了口服避孕药，而检验结果在组间没有不同。在健康的没有症状的控制人口中，初步测试组的平均年龄是49岁(从21到75岁)，而隐蔽测试组的是48岁(从25到73岁)。这些年龄在本质上与那些测试组【(平均58岁(从29到82岁)和隐蔽测试组(平均59岁，从30到80岁)，包括那些1期癌症(平均57岁，从35到75岁)】。在这个年龄分布的基础上，两个测试组很好地代表了绝经前和绝经后的女性，因此绝经情况在检测中不应该是一个影响因素。
杜绝机译，请放心采用。
Study population
研究人群
100 control samples (50 for the preliminary analysis and 50 for the masked analysis) were provided from the National Ovarian Cancer Early Detection Program (NOCEDP) clinic at Northwestern University Hospital (Chicago, IL, USA). 17 other control samples from anonymous women unaffected by cancer were provided by the Simone Protective Cancer Institute (Lawrenceville, NJ, USA). 100个对照样本（50个用于初步分析，50个用于隐蔽的分析）由西北大学医院（美国伊利诺斯州芝加哥）的卵巢癌早期检测计划（NOCEDP）的诊所提供。另外17个来自于没有受癌症影响的、姓名不详的妇女的样本则由西蒙娜保护癌症研究所（美国新泽西州劳伦斯维尔）提供。These 17 women had endometriosis (seven), uterine fibroids (three), sinusitis (four), rheumatoid arthritis (two), and ulcerative colitis (one) and were included in the masked validation set. 这17名妇女患有子宫内膜异位症（7人），子宫纤维瘤（3人），窦炎（4人），类风湿性关节炎（2人）和溃疡性肠炎（1人），并被包括在隐蔽的证实组中。Cases from the NOCEDP were self-referred under at least one of the following eligibility criteria: at least one affected first-degree relative; familial breast or ovarian cancer syndrome; positivity for BRCA1 or BRCA2 mutations; or personal history of breast cancer. 来自NOCEDP的案例在至少下面的资格标准之一下是自荐的：至少有一个受到影响的直系亲属； 家族性乳腺癌或卵巢癌综合征；BRCA1或BRCA2基因突变阳性；或者个人的乳腺癌史。BRCA1/2 status was not made available to this analysis under the conditions of anonymisation. The high-risk population was chosen because availability of a viable management option is particularly important for women who are at increased risk of development of ovarian cancer.
在anonymisation条件下BRCA1/2状态不能用于此分析。选择高风险人群是因为对于正处于卵巢癌发展高风险中的妇女来说，获得一个有生命力的管理选项特别重要。
All women received a yearly three-dimensional colour doppler flow ultrasound examination and measurement of CA125 concentration.6 Cases were defined as unaffected if they had had a minimum of 5 yearly follow-up examinations without diagnosis of ovarian cancer. Cases with ovarian cancer were eligible if they had had a serum sample banked before pathological staging by a gynaecological oncologist.
所有妇女都接受每年一次的、CA125浓度的三维彩色多普勒超声波检查和测量。6个案例被定义为未受影响的，因为她们至少有5年的随访检查是没有诊断出卵巢癌。带有卵巢癌的案例是符合资格的，条件是她们在被妇科肿瘤医生病例分期之前存有一份血清样本。
Simple ovarian cysts were detected by ultrasonography in 38% of the unaffected women (table 1). All major epithelial subtypes of ovarian cancer were represented, and six of the cancer samples were from women with stage I disease, which mirrors the distribution of stage I ovarian cancer in the community. Reported oral contraceptive use and parity was not different between the groups. 在38%的未受影响的妇女中，用超声波图像检测到了简单的卵巢囊肿（表1）。卵巢癌的所有主要的上皮细胞亚型都做了表示，而6个癌的样本来自于患有第一期疾病的妇女，这反映了第一期卵巢癌在公众中的分布。报道的口服避孕药的使用和不均衡在对照组之间没什么差别。The median age in the healthy symptom-free control population was 49 years (range 21–75) in the preliminary set and 48 years (25–73) in the masked validation set. These ages were not substantially different from those for the cancer patients in the preliminary set (median 58 years [range 29–82]) and in the masked validation set (59 [30–80]), including only those with stage I cancers (57 [35–75]). On the basis of the age distribution, premenopausal and postmenopausal women were ally represented in both groups, thus menopausal status should not have been a discriminator in the detection algorithm.在初步组中健康的无症状对照人群的中值年龄为49岁(范围21-75) ，而在隐蔽的证实组中为48岁（范围25－73）。这些年纪与初步组中癌症病人的年纪（中值58岁[范围29－82]）和隐蔽的证实组中癌症病人，包括仅为第一期癌症病人的年纪（59[30-80]没有重大差别。在年龄分布的基础上，绝经前和绝经后的妇女都在两个小组中有所代表，所以月经状态应该对检测算法不是鉴别的因素。
人口研究
西北大学医院（芝加哥，伊利诺州,美国）的全国卵巢癌早期检测程序(NOCEDP)诊所提供了100个控制样品(其中50个是初步分析，50个是隐蔽分析)。西蒙防护癌症研究所（劳伦斯维尔，纽约州，美国）提供了另外17个来自匿名女性的没有患癌的控制样本。其中，这17名女子患有各种病：子宫内膜异位症(7个),子宫肌瘤(3个)、窦炎(4个)、类风湿关节炎(2个)和溃疡性结肠炎(1个)。而这17个控制样本是在进行隐蔽分析的测试组。从NOCEDP得到的病例是经过以下最少的一个标准进行自我诊断的：①至少有一个患病的一级亲属；②家族性乳腺癌或卵巢癌综合征；③对BRCA1或BRCA2基因突变呈显性反应；④个人乳腺癌史。在匿名化的条件下，BRCA1/2的是不适用于这个分析的。选取高危人群是因为对于患卵巢癌风险不断增加的女性来讲，一个多样的管理选项的适用性尤为重要。
所有的妇女接受了年度的三维彩色多普勒超声的检查和CA125浓度的测量。如果她们已经有至少5年度的随访检查没有诊断为卵巢癌，那么有6个病例定义为未受影响。如果她们在妇科肿瘤学家进行病理阶段研究之前有病理分期血清样品，那么这些卵巢癌患者病例是合格的。
38%的没有患病的女性被超声波检测到简单的卵巢囊肿在(表1)。所有主要的卵巢癌上皮细胞亚型是典型代表，而从患有1期的女性所得来的6个癌症样本反映了分布1期癌细胞的分布情况。据报告显示，实验组都使用了口服避孕药，而检验结果在组间没有不同。在健康的没有症状的控制人口中，初步测试组的平均年龄是49岁(从21到75岁)，而隐蔽测试组的是48岁(从25到73岁)。这些年龄在本质上与那些测试组【(平均58岁(从29到82岁)和隐蔽测试组(平均59岁，从30到80岁)，包括那些1期癌症(平均57岁，从35到75岁)】。在这个年龄分布的基础上，两个测试组很好地代表了绝经前和绝经后的女性，因此绝经情况在检测中不应该是一个影响因素。
绝对人工翻译，不过部分专业名词可能翻得不是很好，本人不是理工科出身的。LZ可以自己对照修改一下啊~
内容全部来源于网络收集，如有侵权，请联系网站删除：QQ：24596024